Dienogest, a synthetic steroid, suppresses both embryonic and tumor-cell-induced angiogenesis

Masaki Nakamura, M Nakamura, Yukio Katsuki, Y Katsuki, Yasunori Shibutani, Y Shibutani, T Oikawa, Tsutomu Oikawa
European journal of pharmacology · 1999 · vol. 386(1) , pp. 33–40 · doi:10.1016/s0014-2999(99)00765-7 · PMID:10611461 · W1989326112
article OA: closed CC0 ⤵ 37 in-corpus citations
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06, 2026-06-06 ⓘ

Dienogest, a synthetic steroid, was found to suppress both embryonic and tumor-cell-induced angiogenesis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

MeSH descriptors

Angiogenesis Inhibitors Antineoplastic Agents, Hormonal Embryo, Mammalian Nandrolone Neovascularization, Pathologic Neovascularization, Physiologic Angiogenesis Inhibitors Animals Antineoplastic Agents, Hormonal Cell Division Cell Division Chorion Chorion Depression, Chemical Embryo, Mammalian Endothelium, Vascular Endothelium, Vascular Endothelium, Vascular Female Mice

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (43)

Cited by (37)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:10:24.024533+00:00
License: CC0 · commercial use OK